Targeted Protein Degradation Therapies Treatment 
Drug Discovery World
APRIL 3, 2024
In the last few years, immunotherapies like immune checkpoint inhibitors, vaccines and cell and gene therapies have revolutionised the treatment of cancer, and targeted drugs like monoclonal antibodies (mAbs), poly-ADP ribose polymerase (PARP) inhibitors and targeted protein degraders are also playing an important role.
Drug Discovery World
JANUARY 15, 2024
The collaboration leverages Evotec’s R&D platform to advance drug discovery for two drug targets that address major unmet medical needs of patients with Crohn’s disease and ulcerative colitis. of Perspective’s shares for up to $33 million. of Perspective’s shares for up to $33 million.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
MARCH 22, 2023
It will combine the use of novel Huntington’s disease drug targets from Aitia’s Gemini Digital Twins with UCB’s expertise in drug research and preclinical model systems in neurodegeneration, with the aim to accelerate the discovery of new therapies for people living with Huntington’s disease.
Drug Discovery World
DECEMBER 27, 2023
MDC is part of the Catapult Network established by Innovate UK and has a vision to reshape drug discovery for the benefit of patients by transforming great UK science into better treatments through partnership. and seizure liability testing What are the benefits of a target safety assessment? Listen here.
Covalent Modifiers
FEBRUARY 1, 2024
Covalent and noncovalent inhibitors of BTK have revolutionized the treatment of these cancers. Therefore, understanding mechanisms by which acquired mutations in BTK confer drug resistance and developing new therapies to overcome resistance are critically important.
Drug Discovery World
OCTOBER 6, 2022
It is therefore not surprising that Switzerland played an important role in the global effort to combat the pandemic, and that two Swiss based companies were successful in developing treatments to combat Covid infections (Humabs BioMed/Vir Biotechnology and Molecular Partners/Novartis).” . billion, equivalent to $3.7 References: .
Drug Discovery World
OCTOBER 16, 2023
A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. The university aims to identify treatments for life-threatening anti-microbial diseases and metabolic disorders.
Expert insights. Personalized for you.
130 
Let's personalize your content